Brian T. Burger,Benjamin P. Beaton,Matthew A. Campbell,Benjamin T. Brett,Melissa S. Rohrer,Sarah Plummer,Dylan Barnes,Ke Jiang,Sudhir Naswa,Jeremy Lange,Alina Ott,Elizabeth Alger,Gonzalo Rincon,Steven Rounsley,Jeff Betthauser,Namdori R. Mtango,Joshua A. Benne,Jessica Hammerand,Codie J. Durfee,Marisa L. Rotolo,Peter Cameron,Alexandra M. Lied,Matthew J. Irby,David B. Nyer,Chris K. Fuller,Scott Gradia,Steven B. Kanner,Ki-Eun Park,Jerel Waters,Sean Simpson,Bhanu P. Telugu,Brianna C. Salgado,Alberto Brandariz-Nuñez,Raymond R.R. Rowland,Matt Culbertson,Elena Rice,A. Mark Cigan

Abstract:Disease resistance genes in livestock provide health benefits to animals and opportunities for farmers to meet the growing demand for affordable, high-quality protein. Previously, researchers used gene editing to modify the porcine CD163 gene and demonstrated resistance to a harmful virus that causes porcine reproductive and respiratory syndrome (PRRS). To maximize potential benefits, this disease resistance trait needs to be present in commercially relevant breeding populations for multiplication and distribution of pigs. Toward this goal, a first-of-its-kind, scaled gene editing program was established to introduce a single modified CD163 allele into four genetically diverse, elite porcine lines. This effort produced healthy pigs that resisted PRRS virus infection as determined by macrophage and animal challenges. This founder population will be used for additional disease and trait testing, multiplication, and commercial distribution upon regulatory approval. Applying CRISPR-Cas to eliminate a viral disease represents a major step toward improving animal health.

Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas